Nottingham, UK (17 September 2008). Novozymes Biopharma, part of Novozymes, world leader in bioinnovation, announces a new development in animal-free supplements for industrial cell culture on booth #219 at BioProcess International Conference and Exhibition, 23-26 September 2008, Disneyland Hotel, Anaheim, CA, USA.

Novozymes Biopharma, specialists in large scale recombinant protein production for the biopharmaceutical industry, unveils the first product under the CellPrime™ brand. Novozymes’ Transferrin recombinant supplement is now commercially ready in scalable manufacturing quantities for consistency of supply.

Designed to reduce risk and ease regulatory concerns for biopharmaceutical manufacturers, this new advance will improve the consistency and productivity of customers’ industrial cell culture process. Manufactured by Novozymes Biopharma, Transferrin is sold exclusively through Millipore Corporation as part of the CellPrime alliance announced in December 2007.

Novozymes Biopharma will also exhibit its two key product lines, Recombumin® and LONG®R3 IGF-I, on booth #219. Recombumin® is a yeast derived recombinant human albumin, which has a structure identical to human serum albumin (HAS). It is the world’s first and only animal-free recombinant human albumin approved for use in the manufacture of human therapeutics. LONG®R3 IGF-I is an analogue of human insulin-like growth factor I (IGF-I) specifically engineered by Novozymes Biopharma for use in industrial cell culture. LONG®R3 IGF-I provides improved performance and a consistent, compliant and animal-free alternative to recombinant insulin.

Novozymes Biopharma’s portfolio includes biopharmaceutical technologies and services, contract manufacturing of pharmaceutical grade biological APIs, and services such as cell banking, technology transfer and process development.

Novozymes Biopharma demonstrates in-depth expertise during the technical conference with:-
• A poster display on “Advances in animal free media supplements for optimal cell culture performance,” presented by Sally Grosvenor, Senior Scientist and Scientific Communications Manager, Novozymes Biopharma AU Ltd. In the poster area, Disneyland Hotel, Anaheim.
• A workshop, entitled “Cell Culture and Processing Track” hosted by Sally Grosvenor, on 25th September 2008 at Magic Kingdom 2 and 3 at 12-12.30pm, will discuss the ability of two key serum proteins, Transferrin and IGF-I, to stimulate cell growth and productivity.
• Geoff Francis, Chief Scientist, Novozymes Biopharma AU Ltd is moderator of the Novozymes sponsored Panel Discussion “Cell Engineering the Future – A Role for Media Innovation” 12.30pm on 25th September 2008.

To learn more about Novozymes Biopharma’s portfolio of products, please visit booth #219 at BioProcess International Conference and Exhibition 2008. Alternatively please email Sally Kent, Marketing Manager, at This email address is being protected from spambots. You need JavaScript enabled to view it. or visit www.biopharma.novozymes.com

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace.

Novozymes’ natural solutions enhance and promote everything from removing trans-fats in food, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 4,500 patents, showing what is possible when nature and technology join forces.

Our 4,500+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.